- PR Newswire•11 days agoAethlon Medical Achieves DARPA Milestones, Including Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Validation
SAN DIEGO, Oct. 13, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), announced today that it has completed multiple milestone achievements under a contract with the Defense Advanced Research Projects Agency (DARPA), including a milestone validation that the Aethlon Hemopurifier® is able to capture the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The Hemopurifier® is a first-in-class medical device designed to rapidly eliminate viral pathogens from the circulatory system of infected individuals. The MERS-CoV milestone was predicated on demonstrating the capture of the virus with small-scale versions of the Aethlon Hemopurifier. According to the Centers for Disease Control and Prevention (CDC), Middle East Respiratory Syndrome (MERS) is an illness caused by MERS-CoV infection. The virus was first reported in Saudi Arabia in 2012 and has since spread to several other countries, including the United States. Most people identified as infected with MERS-CoV develop severe acute respiratory illness, including fever, cough and shortness of breath. The World Health Organization (WHO) has reported 1,806 laboratory-confirmed cases of MERS-CoV infection, resulting in 643 deaths. There is no vaccine or antiviral drug to treat MERS-CoV.
- PR Newswire•12 days ago
SAN DIEGO, Oct. 12, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), announced today that Jim Joyce, Chairman and CEO, will be presenting a corporate update at the 2016 Bio Investor Forum in San Francisco, CA at 6:30 p.m. ET (3:30 a.m. PT) on Tuesday, October 18, 2016. The presentation will be made available to the public via live audio webcast which can be accessed by visiting the investor relations section of Aethlon Medical's corporate website at http://www.aethlonmedical.com. Aethlon Medical (AEMD) is a leading developer of immunotherapeutic technologies to combat infectious disease and cancer. To augment the body's natural immune defenses, the Aethlon Hemopurifier® eliminates life-threatening disease targets that are often shielded from the immune system and not well addressed by traditional drug therapies.
- PR Newswire•last month
SAN DIEGO, Sept. 20, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), today announced changes to its corporate presentation schedule over the coming month. On September 6th, the Company disclosed that its Chairman and CEO, Jim Joyce, would be presenting at the Aegis Capital 2016 Annual Growth Conference on Wednesday, September 21st. Instead, Mr. Joyce will now participate in the Anti-Infectives RX Conference, taking place at Harvard Medical School in Boston, MA on Wednesday, September 21st. Mr. Joyce will serve on the Advances Against Rare and Resistant Pathogens panel at 2:20 p.m. ET (11:20 a.m. PT). As a result, Mr. Joyce's presentation at the Aegis Capital 2016 Annual Growth Conference has been moved to 2:30 p.m. ET (11:30 a.m. PT) on Thursday, September 22nd. The Aegis conference will take place at The Encore at Wynn in Las Vegas, NV. For more information and registration, please visit the conference website.
Aethlon Medical, Inc. (AEMD)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Bid||4.56 x 200|
|Ask||4.70 x 300|
|Day's Range||4.40 - 4.76|
|52wk Range||4.02 - 9.09|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-6.15|
|Avg Vol (3m)||44,490|
|Dividend & Yield||N/A (N/A)|